Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.
Browsing: Taxonomy > Immunotherapy
A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study.
Checkpoint inhibitors increase median survival to 12.4 months, and more than double percentage of patients who survive 4 years or longer.
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
The Phase III IMpassion130 study, investigating TECENTRIQ® plus Abraxane® for triple-negative breast cancer, has met its progression-free survival endpoint.
Choosing when to stop immunotherapy is an extremely difficult decision process – in this blog piece melanoma survivor T.J. Sharpe shares his thoughts on the recent KEYNOTE-006 data.
A genetic test could aid the identification of men with prostate cancer who are most likely to benefit from immunotherapy.
A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
We have brought together our top takeaways from the five days of ASCO 2018.
A study presented at the American Society of Clinical Oncology Annual Meeting (ASCO, 1–5 June 2018, IL, USA) has revealed…